[1]谭燕,颜高姝,刁鹏,等.促性腺激素释放激素激动剂对辐射所致大鼠卵巢功能损伤的防护作用研究[J].国际放射医学核医学杂志,2017,41(5):314-320.[doi:10.3760/cma.j.issn.1673-4114.2017.05.002]
 Tan Yan,Yan Gaoshu,Diao Peng,et al.Protective effect of gonadotropin-releasing hormone agonist on ovarian functional impairment caused by radiation in rats[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):314-320.[doi:10.3760/cma.j.issn.1673-4114.2017.05.002]
点击复制

促性腺激素释放激素激动剂对辐射所致大鼠卵巢功能损伤的防护作用研究(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第5期
页码:
314-320
栏目:
论著
出版日期:
2017-09-25

文章信息/Info

Title:
Protective effect of gonadotropin-releasing hormone agonist on ovarian functional impairment caused by radiation in rats
作者:
谭燕 颜高姝 刁鹏 范子煊 孙春堂
610041 成都, 四川省肿瘤医院·研究所放疗中心, 四川省癌症防治中心, 电子科技大学医学院
Author(s):
Tan Yan Yan Gaoshu Diao Peng Fan Zixuan Sun Chuntang
Department of Radiotherapy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China
关键词:
辐射耐受性放射疗法卵巢辐射防护促性腺激素释放激素激动剂
Keywords:
Radiation toleranceRadiotherapyOvaryRadiation protectionGonadotropin-releasing hormone agonist
DOI:
10.3760/cma.j.issn.1673-4114.2017.05.002
摘要:
目的 探讨促性腺激素释放激素激动剂(GnRHa)对盆腔放疗辐射所致大鼠卵巢功能损伤的保护作用及可能机制。方法 实验1:雌性Fischer 344大鼠5只,于动情间期皮下给予GnRHa 0.25 mg后,动态观察其血清卵泡刺激素(FSH)、雌二醇(E2)及抗苗勒管激素(AMH)水平变化情况。实验2:雌性大鼠40只,以随机数字表法分为对照组、GnRHa组、放疗组(R组)及GnRHa+R组并给予相应处理,盆腔照射后20 d,采用单因素方差分析及独立样本t检验比较各组间的体重、卵巢湿重、血清FSH、E2、AMH水平及卵泡数量的差异。对比各组大鼠卵巢凋亡指数和微血管密度。结果 实验1:皮下给予GnRHa后,大鼠卵巢功能受到抑制,FSH、E2水平持续下降,15 d左右达到谷值,再过20 d后恢复至给药前水平。实验2:盆腔放疗后,GnRHa+R组、R组与对照组相比均出现不同程度的卵巢功能损伤,但GnRHa+R组与R组相比受损程度较轻,表现为E2水平偏高(t=12.79,P<0.01),FSH水平偏低(t=4.65,P<0.01),AMH水平偏高(t=5.65,P<0.01);卵泡计数显示,GnRHa+R组的原始及初级卵泡数显著高于R组(t=7.70,P<0.01);Tunnel和CD31染色结果显示R组卵巢内细胞凋亡指数和微血管密度显著高于GnRHa+R组(t=8.20和9.83,均P<0.05)。结论 放疗前应用GnRHa能够有效减轻放疗辐射对大鼠卵巢功能的损伤,这可能与GnRHa将卵泡发育抑制在原始、初级卵泡阶段以及减少卵巢组织血供及氧合进而降低卵巢放射敏感性有关。
Abstract:
Objective To investigate the protective effect of gonadotropin-releasing hormone agonist (GnRHa) on ovarian function in rats during pelvic irradiation and its possible mechanism. Methods 1. Five female Fischer-344 rats were subcutaneously injected with 0.25 mg of GnRHa. Changes in serum follicle -stimulating hormone(FSH), estradiol(E2), and anti -mullerian hormone(AMH) levels were observed continually. 2. Forty female rats were randomly divided into four groups(Control, GnRHa, R, and GnRHa+ R) and given their corresponding treatments. At 20 days after pelvic irradiation, the weight; ovarian wet weight; serum FSH, E2, and AMH levels; and follicular numbers of the four groups were compared using one-way ANOVA and independent-sample t-test. The apoptotic index and microvessel density(MVD) in the ovarian tissue of each group were also compared. Results 1. Treatment with GnRHa inhibited ovarian function. Under this treatment, serum FSH and E2 declined, reached the minimum values in approximately 15 days, and then normalized in approximately 20 days. 2. After pelvic radiotherapy, the GnRHa+R and R groups showed different degrees of ovarian function damage compared with the control group, but the damage to the GnRHa +R group was less severe compared with that to the other groups. The GnRHa +R group showed higher E2(t=12.79, P<0.01), lower FSH(t=4.65, P<0.01), and relatively higher AMH (t=5.65, P<0.01) compared with the R group. Follicular classification revealed significantly more primordial and primary follicles in the GnRHa+R group than in the R group(t=7.70, P<0.01). Tunnel and CD31 staining showed that the apoptotic index and MVD were significantly higher in the R group than in the GnRHa+R group(t=8.20 and 9.83, both P<0.05). Conclusions Administration of GnRHa before radiotherapy can significantly decrease radiation damage to ovarian function in rats. GnRHa exerts its protective effect against ovarian functional impairment by inhibiting follicular development in primordial and primary follicles. It decreases the blood supply and oxygen of ovarian tissue, thereby reducing the radiation sensitivity of the ovary.

参考文献/References:

[1] Anderson RA, Hindmarsh PC, Wallace W. Induction of puberty by autograft of cryopreserved ovarian tissue in a patient previously treated for Ewing sarcoma[J]. Eur J Cancer, 2013, 49(13):2960- 2961. DOI:10.1016/j.ejca.2013.04.031.
[2] Kim J, Kim M, Lee JH, et al. Ovarian function preservation with GnRH agonist in young breast cancer patients:Does it impede the effect of adjuvant chemotherapy?[J]. Breast, 2014, 23(5):670-675. DOI:10.1016/j.breast.2014.07.005.
[3] Del Mastro L. Temporary ovarian suppression with goserelin and ovarian function protectio n in patients with breast cancer undergoing chemotherapy[J]. J Clin Oncol, 2011, 29(24):3339- 3340. DOI:10.1200/JCO.2011.36.9942.
[4] Moore HC, Unger JM, Albain KS. Ovarian protection during adjuvant chemotherapy[J]. N Engl J Med, 2015, 372(23):2269- 2270. DOI:10.1056/NEJMc1504241.
[5] Mahran YF, El-Demerdash E, Nada AS, et al. Insights into the protective mechanisms of tamoxifen in radiotherapy -induced ovarian follicular loss:impact on insulin-like growth factor 1[J]. Endocrinology, 2013, 154(10):3888-3899. DOI:10.1210/en.2013- 1214.
[6] Meng L, Rijntjes E, Swarts HJ, et al. Prolonged hypothyroidism severely reduces ovarian follicular reserve in adult rats[J/OL]. J Ovarian Res, 2017, 10(1):10[2017-07-04]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356350.DOI:10.1186/s13048-017- 0314-7.
[7] Hardy K, Fenwick M, Mora J, et al. Onset and heterogeneity of responsiveness to FSH in mouse preantral follicles in culture[J]. Endocrinology, 2017, 158(1):134-147. DOI:10.1210/en.2016-1435.
[8] 徐文清, 高文远, 沈秀, 等. 银耳多糖注射剂保护辐射损伤小鼠造血功能的研究[J]. 国际放射医学核医学杂志, 2006, 30(2):114- 116. Xu WQ, Gao WY, Shen X, e t al. Protective effect study of polysaccharides from tremellafuciformis on hematopoietic function in radiation-injured mice[J]. Int J Radiat Med Nucl Med, 2006, 30(2):114-116.
[9] Broer SL, Van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy:an individual patient data approach[J]. Hum Reprod Update, 2012, 19(1):26-36. DOI:10.1093/humupd/dms041.
[10] Landoni F, Colombo A, Milani R, et al. Randomized study between radical surgery and radiotherapy for the treatment of stage ⅠB-ⅡA cervical cancer:20-year update[J/OL]. J GynecolOncol, 2017, 28(3):e34[2017-07-04]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391393.DOI:10.3802/jgo.2017.28.e34.
[11] Jadoul P, Dolmans MM, Donnez J. Fertility preservation in girls during childhood:is it feasible, efficient and safe and to whom should it be proposed?[J]. Hum Reprod Update, 2010, 16(6):617- 630. DOI:10.1093/humupd/dmq010.
[12] Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med, 2015, 372(10):923-932. DOI:10.1056/NEJMoa1413204.
[13] Li X, Kang X, Deng Q, et al. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity:a controlled experimental animal study[J/OL]. Reprod Biol Endocrinol, 2013, 11:16[2017-07-04]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598983.DOI:10.1186/1477-7827-11-16.
[14] Rodriguez-Wallberg K, Turan V, Munster P, et al. Can ovarian suppression with gonadotropin-releasing hormone analogs(GnRHa) preserve fertility in cancer patients?[J]. AnnOncol, 2016, 27(2):357-365. DOI:10.1093/annonc/mdv554.
[15] Blumenfeld Z, Zur H, Dann EJ. Gonadotropin -releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors[J]. Oncologist, 2015, 20(11):1283-1289. DOI:10.1634/theoncologist. 2015-0223.
[16] Grande M, Borobio V, Bennasar M, et al. Role of ovarian reserve markers, antimüllerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages[J]. Fertil Steril, 2015, 103(5):1221-1227. DOI:10.1016/j.fertnstert. 2015. 02.022.
[17] Brodin T, Hadziosmanovic N, Berglund LA, et al. Comparing four ovarian reserve markers-associations with ovarian response and live births after assisted reproduction[J]. Acta Obstet Gynecol Scand, 2015, 94(10):1056-1063. DOI:10.1111/aogs.12710.
[18] Arouche N, Picard JY, Monniaux D, et al. The BOC ELISA, a ruminant-specific AMH immunoassay, improves the determination of plasma AMH concentration and its correlation with embryo production in cattle[J]. Theriogenology, 2015, 84(8):1397-1404. DOI:10.1016/j.theriogenology. 2015.07.026.
[19] Mahran YF, El-Demerdash E, Nada AS, et al. Growth hormone ameliorates the radiotherapy-induced ovarian follicular loss in rats:impact on oxidative stress, apoptosis and IGF-1/IGF-1R axis[J/OL]. PLoS One, 2015, 10(10):e0140055[2017-07-04]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140055.DOI:10. 1371/journal.pone.0140055.
[20] Song G, Chen Y, Liang C, et al. Catalase-loaded TaOx nanoshells as bio -nanoreactors combining high -Z element and enzyme delivery for enhancing radiotherapy[J]. Adv Mater, 2016, 28(33):7143-7148. DOI:10.1002/adma.201602111.
[21] Said RS, El-Demerdash E, Nada AS. Resveratrol inhibits inflammatory signaling implicated in ionizing radiation-induced premature ovarian failure through antagonistic crosstalk between silencing information regulator 1(SIRTI) and poly(ADP-ribose) polymerase 1(PARP-1)[J]. Biochem Pharmacol, 2016, 103(103):140-150. DOI:10.1016/j.bcp.2016.01.019.
[22] Wang R, Lin S, Wang Y, et al. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve:a systematic review and meta-analysis[J/OL]. PLoS One, 2017, 12(4):e0175985[2017-07-04]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175985.DOI:10.1371/journal.pone.0175985.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
 Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
 Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
 Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
 Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[5]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
 zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[6]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
 Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[7]段永璇,邹晓艳,段秀梅,等.数据解析在肿瘤放射治疗中的应用[J].国际放射医学核医学杂志,2015,39(6):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
 Duan Yongxuan,Zou Xiaoyan,Duan Xiumei,et al.Data analysis in the field of tumor radiation therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
[8]贾立立,孟粹达,刘晓冬,等.头颈部肿瘤放疗中转化医学相关机制的研究进展[J].国际放射医学核医学杂志,2015,39(3):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
 Jia Lili,Meng Cuida,Liu Xiaodong,et al.Development in translational medicine-related mechanisms of radiotherapy for head and neck cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
[9]曹婉婷,李浣洋,陈雪英,等.正常组织在放射治疗中并发的迟发性损伤[J].国际放射医学核医学杂志,2015,39(3):260.[doi:10.3760/cma.j.issn.1673-4114.2015.03.016]
 Cao Wanting,Li Huanyang,Chen Xueying,et al.Late effects of radiotherapy on normal tissue[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):260.[doi:10.3760/cma.j.issn.1673-4114.2015.03.016]
[10]杜芳芳,郭阳,姜炜.脑转移瘤的放射治疗进展[J].国际放射医学核医学杂志,2015,39(4):328.[doi:10.3760/cma.j.issn.1673-4114.2015.04.012]
 Du Fangfang,Guo Yang,Jiang Wei.Advances in radiotherapy of brain metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):328.[doi:10.3760/cma.j.issn.1673-4114.2015.04.012]
[11]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
 Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[12]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
 Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[13]殷丽娜,张旭霞,张俊香,等.Wnt/β-catenin信号通路——乳腺癌的潜在治疗靶点[J].国际放射医学核医学杂志,2014,38(4):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
 Yin Lina,Zhang Xuxia,Zhang Junxiang,et al.The Wnt/β-catenin signaling pathway-a potential therapeutic target of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
[14]翟红彦,苏成海.基因治疗联合放射治疗恶性肿瘤的分子机制[J].国际放射医学核医学杂志,2009,33(2):113.[doi:10.3760/cma.j.issn.1673-4114.2009.02.015]
 ZHAI Hong-yan,SU Cheng-hai.Molecular mechanism of genetherapy combined radiotherapy for malignant tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(5):113.[doi:10.3760/cma.j.issn.1673-4114.2009.02.015]
[15]谭燕,孙春堂,颜高姝,等.促性腺激素释放激素拮抗剂对盆腔放疗所致卵巢功能损伤的防护作用[J].国际放射医学核医学杂志,2018,(5):420.[doi:10.3760/cma.j.issn.1673-4114.2018.05.006]
 Tan Yan,Sun Chuntang,Yan Gaoshu,et al.Protective effect of gonadotropin releasing hormone antagonist on ovarian function injury induced by pelvic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):420.[doi:10.3760/cma.j.issn.1673-4114.2018.05.006]

备注/Memo

备注/Memo:
收稿日期:2017-07-04。
基金项目:四川省科技厅应用基础面上项目(2017JY0298)
通讯作者:孙春堂,Email:sunrise14@163.com
更新日期/Last Update: 2017-09-25